EU approves Vertex’ cystic fibrosis combo
The European Commission has approved Vertex’ Symveki in a combination regimen with Kalydeco to treat certain patients with cystic fibrosis (CF).
Read Moreby Selina McKee | Nov 1, 2018 | News | 0
The European Commission has approved Vertex’ Symveki in a combination regimen with Kalydeco to treat certain patients with cystic fibrosis (CF).
Read Moreby Selina McKee | Oct 9, 2018 | News | 0
Novartis is seeking approval on both sides of the Atlantic for use of experimental multiple sclerosis therapy siponimod to treat secondary progressive forms of the disease.
Read Moreby Selina McKee | Sep 19, 2016 | News | 0
Novartis has unveiled further findings from a late-stage trial of its experimental multiple sclerosis drug BAF312 (siponimod), showing that the drug cut the risk of disability progression in adults with secondary progressive forms of the disease.
Read Moreby Selina McKee | Aug 26, 2016 | News | 0
Novartis’ experimental multiple sclerosis drug siponimod has hit its key target in a late-stage trial, raising hopes for a new treatment option for patients.
Read More





PharmaTimes Media Ltd.
44 Maiden Lane
Covent Garden
London
WC2E 7LN
E: editorial@pharmatimes.com
E: subscriptions@pharmatimes.com
T: +44 (0)20 7240 6999
